MARKET

MDXG

MDXG

Mimedx Group Inc
NASDAQ
7.40
+0.24
+3.35%
After Hours: 7.24 -0.16 -2.16% 17:12 07/22 EDT
OPEN
7.18
PREV CLOSE
7.16
HIGH
7.43
LOW
7.18
VOLUME
476.26K
TURNOVER
0
52 WEEK HIGH
9.27
52 WEEK LOW
5.57
MARKET CAP
1.09B
P/E (TTM)
21.82
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDXG last week (0715-0719)?
Weekly Report · 1d ago
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
Barchart · 1d ago
CASSAVA SCIENCES INC: RENEWAL OF QUARTERLY ANALYST CALLS
Reuters · 6d ago
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
MiMedx Group, Inc. Will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 31, 2024. The company will host a webcast and conference call to review its results on the same day.
Barchart · 6d ago
Weekly Report: what happened at MDXG last week (0708-0712)?
Weekly Report · 07/15 09:48
Weekly Report: what happened at MDXG last week (0701-0705)?
Weekly Report · 07/08 09:49
Analyst Bullish On MiMedx's Rapid Growth In $4B Woundcare Market With Innovative Skin Substitutes
Cantor Fitzgerald has initiated coverage on MiMedx Group Inc. The company is a provider of a product portfolio for applications in wound care, burn, and surgical recovery. MIMEDX’s technologies target a $3.9 billion market. Cantor initiates with an Overweight rating and a price target of $11.
Benzinga · 07/02 18:32
Cantor starts MiMedx at overweight, cites valuation, product offerings
Cantor Fitzgerald starts MiMedx at overweight, cites valuation, product offerings. The investment bank has a $11 price target for the stock. The company's product portfolio is "differentiated and protected," Cantor says. MiMedX Group, Inc. Is a wound care product maker.
Seeking Alpha · 07/02 18:15
More
About MDXG
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

Webull offers MiMedx Group Inc stock information, including NASDAQ: MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.